Belén Garijo, Merck KGaA CEO (Arne Dedert/picture-alliance/dpa/AP Images)
Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends
Merck KGaA reported Monday that it had regained full rights to its PD-L1 antibody Bavencio after a nearly 10-year alliance with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
